Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
REDWOOD CITY, Calif., Feb. 02, 2016 -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the 18th Annual BIO CEO & Investor Conference on February 9, 2016 at 1:00 p.m. ET.
To access the live webcasts and subsequent archived recordings of these presentations, please visit Relypsa's website at http://investor.relypsa.com/events.cfm.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company’s first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa’s rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Alex Dobbin
Associate Director, Investor Relations
650-421-9687
[email protected]
